Many studies have been conducted for the feasibility of using dexmedetomidine as
premedication. However, bradycardia and hypotension frequently occurred following the
premedication with dexmedetomidine, either via intramuscular or intravenous route. This is
particularly true when using a high dose of dexmedetomidine: a intramuscular dose over 2
μg•kg-1 or a intravenous dose over 1 μg•kg-1 can elicit marked decreases in heart rate and
mean arterial blood pressure. Subsequent studies using high-dose dexmedetomidine further
revealed the potential impact of its detrimental haemodynamic profile on clinical outcomes.
Most studies using high-dose dexmedetomidine were predominantly adopted with the dose-finding
study performed by Aho and colleague, whom reported that 2.5 μg•kg-1 dose of intramuscular
dexmedetomidine was comparably sedative and anxiolytic to 0.08 mg•kg-1 midazolam. However,
few investigations have addressed the clinical effects of low-dose dexmedetomidine as
premedication. Considering modern anaesthesia has advanced a long way towards eliminating the
routine need for a deep preoperative sedation. It has, therefore, become desirable to asses
dexmedetomidine as an effective premedication using a moderate sedative dose to minimize its
undesired hemodynamic effects. We set a prospective study to compare the sedative,
haemodynamic, adjuvant anaesthetic effects and patient's satisfaction of low-dose
dexmedetomidine (1μg•kg-1) with midazolam (0.03 mg•kg-1), the most commonly used
premedication, used as an intramuscular injective administration in patients undergoing
suspension laryngoscopic surgery under general anaesthesia.
Phase:
Phase 4
Details
Lead Sponsor:
Guangzhou First Municipal People’s Hospital Guangzhou First People's Hospital